December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Central Corneal Thickness During Treatment with Latanoprost and Dorzolamide
Author Affiliations & Notes
  • RP Stodtmeister
    Private Practice Pirmasens Germany
  • M Kron
    Department ofBiometry and Medical Documentation University of Ulm Ulm Germany
  • Footnotes
    Commercial Relationships    R.P. Stodtmeister, Chibret C; M. Kron, Chibret C. Grant Identification: None
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4219. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      RP Stodtmeister, M Kron; Central Corneal Thickness During Treatment with Latanoprost and Dorzolamide . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4219.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: The pressure lowering effect of Latanoprost eye drops may be caused by a reduction of collagens within the uveoscleral outflow pathway. We have put the hypothesis forward, that topically applied Latanoprost may reduce the collagens in the cornea and that this change could be assessed by ultrasound pachometry. This hypothesis has been checked in a retrospective study in glaucoma patients with topical Latanoprost treatment and for comparison with topical Dorzolamid treatment. Methods: Latanoprost group: 21 males, 21 females; age: (minimum-median-maximum) 50-67-89; follow-up time: 5-21-26 month. Dorzolamid group: 21 males, 21 females; age: 44-69-87; follow-up time: 7-20-27 month. Ultrasound pachometry unit: Pachette (DGH Technology/Technomed). The data was evaluated by multiple linear regression. Results: Latanoprost group: Decrease of corneal thickness in females by -1.0 m/month (p=0.001) and in males by -0.57 m/month (p=0.055). Dorzolamid group: Increase of corneal thickness in females by 0.16 m/month (p=0.547) and in males by 0.51 m (p=0.061). Discussion: The comparison of two treatment groups was done in order to avoid methodological errors. The data shows that corneal thickness decreases during Latanoprost treatment. This observation may be caused by a reduction of collagens according to observations in animals. The difference in the decrease of corneal thickness in females and males may be explained by observations in animals. The increase of corneal thickness during Dorzolamid treatment in males has been observed in previous studies. Conclusion: Corneal thickness shows a decrease by topical Latanoprost treatment and a less pronounced increase by Dorzolamid treatment.

Keywords: 374 cornea: stroma and keratocytes • 514 pharmacology • 390 drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×